#### **REDPOINT**

### Diagnosis by a skin-prick

Transforming skin diagnosis with IgE-based in situ immunology



## WHO vision: eradicate leprosy by 2030



## Let's eradicate leprosy


#### The problems

- Current diagnostics are too expensive and complicated
- Diagnosis of people with skin lesions only ->
   Unsymptomatic carriers remain as an undetected reservoir

- Success now seems unlikely
- Need for a simple, quick and inexpensive diagnostic

## The innovation – invert the allergy test!

- In a conventional allergy test, allergens are pricked into the skin.
- If IgE the type of antibody that is responsible for the allergic response – against that allergen is present under the skin, the allergen binds to IgE.
- This binding of an allergen to its specific IgE then triggers the allergic response




### Skin prick test for detecting skin pathogens

#### The idea:

IgE specific for a pathogen is pricked into the skin. And if said pathogen is present in the skin, an allergic reaction should develop. Can it be reversed?

This would make the identification of any biomolecule in the skin possible



## The skin-prick test is suitable for diagnosis

- An IgE against a skin protein (FGFR3) was pricked into the skin of the founder.
- An allergic reaction developed quickly (within 5-10 minutes) and started to fade after about 2 hours, leaving no traces on the following day.
   No negative systemic effects were observed.



100µg/ml of an anti-FGFR3 IgE, used in a pair with the buffer contro (marked with " - " and " + ", respectively).

### **Material costs**

100\$

Production costs for GMP-grade monoclonal antibodies are currently around 100\$ per gram 100ng

of IgE per test

1 gram of IgE should be sufficient for about 10.000.000 tests

You can screen Austria for 100\$!



# Estimated market – leprosy and beyond

- Worldwide 200.000 new cases of Leprosy per year
- BUT: Eradication of Leprosy will need population-wide screens
- A screen of the global risk areas would generate 1000 Mio total for a test priced at 2 USD

Redpoint is a platform technology!

An expansion of the concept to other skin infections would dramatically increase the overall sales potential

# Redpoint is looking for ...



complete development

Investor

fund developmen



Dr. Ludwig Englmeier

Biochemist

Patent Attorney (EP and DE)

... So let's eradicate leprosy!